An interventional study of Mediterranean diet in Cystic Fibrosis (CF) and Cystic Fibrosis Gastrointestinal Disease, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 2 sites in United States. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 353rd largest by planned enrollment of the 517 interventional ones that give a count, is one of 16 that started in 2026, is one of 155 with no phase, reaches primary completion later than 47 of the 108 other live ones, and was the 701st registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
Chris Goss · Sites in United States
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Dartmouth-Hitchcock Medical Center is the lead sponsor of 489 studies on the registry; 69 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 21 (68%) have results posted.
Dartmouth-Hitchcock Medical Center has 8 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is no study to date that has evaluated the impact or effect of a Mediterranean diet in children with CF. The goal of this study would be to help provide better guidance around questions the investigators, as CF care providers continue to receive from patients and families about how to best promote overall health in pediatric cystic fibrosis from a dietary perspective. Currently, the updated nutritional recommendations are variable and broad. Parents continue to search for more concrete guidance about how best to promote long-term health given the ever-increasing life expectancy of cystic fibrosis patients in this new area of advanced therapeutics. Given the changing landscape of the CF care in general, children are less likely to struggle with early life malnutrition, and it is becoming increasingly clear that high fat, high calorie diets are not beneficial nor are necessary for all children with CF.
The dietary needs of children with Cystic Fibrosis continue to change. With the advent of highly effective modulator therapy, these needs are profoundly shifting away from the standard advice of high calorie, high fat to varied, regular and moderated calorie. Obesity is a problem the investigators now confront with regularity and has prompted the need for more specific, dietary advice to parents who are eager to find sustainable meal plans that promote health overall.
There is significant data to suggest that the Mediterranean Diet is the pinnacle of dietary health in everything from metabolic syndrome to ADHD in children. As the investigators look to shift away from the standard approach, the investigators are left to consider how specific dietary intervention may be able to support children with cystic fibrosis. Recent studies suggest Mediterranean diet and those similar were associated with increased abundance of fiber degrading bacteria like Ruminococcus as well as subclinical decreases in fecal calprotectin, a marker of gastrointestinal inflammation. In other inflammatory disease, the Mediterranean diet has also been considered as an adjunctive therapy in mild Crohn's and well as ulcerative colitis disease given its anti-inflammatory properties. Specifically in UC, notable microbiome shifts toward increased production of short chain fatty acids which can have a protective, immunomodulatory role in the gut. Data has shown that the CF gut microbiome is different than it's healthy counterparts and often described as a mix of dysbiosis and low grade chronic inflammation. If the investigators could address the underlying inflammation and dysbiosis in a substantial way with an anti-inflammatory dietary intervention, there is potential to decrease the burden of GI disease and symptomatology that persists despite the widespread use of highly effective modulator therapy.
AIM 1: To test the hypothesis that adherence to a Mediterranean Diet will result in alterations to the gastrointestinal microbiome. The investigators would plan to collect fecal samples for microbiota sequencing before starting a strict Mediterranean diet and then again after completion to assess for specific alterations or signatures in microbial diversity as well as other cytokine or metabolomic alterations. Our translational research core already has infrastructure set up for this process through the Dartmouth Infant and Child CF Cohort Study and many of our families are already familiar with this process.
AIM 2: To test the hypothesis that adherence to a Mediterranean Diet will result in reduction in subclinical markers of gastrointestinal inflammation. Stool calprotectin measurements from samples before and after the study period will allow us to assess for alterations.
AIM 3: To test the hypothesis that adherence to a Mediterranean Diet will result in improvement in gastrointestinal symptoms, the investigators would also employ the PAGY-SYM, which is a widely used gastrointestinal symptom tracker to identify any significant changes in GI symptomatology before and after the anticipated diet window.
AIM 4: To test the hypothesis that adherence to a Mediterranean Diet will result in normalization of anthropometric data the investigators will collect clinical information on subject weight, height, BMI Z score as well as mid upper arm circumference as a way to measure relative nutritional status and fat storage.
Study Endpoints:
Primary: Subjects will adhere to 6 months of exclusive Mediterranean Diet and have post diet intervention analysis of 16s and metagenomic sequencing, cytokine and metabolomic analysis for microbiome assessment.
Secondary: Fecal calprotectin as a marker of intestinal inflammation. Patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) for symptom reporting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mediterranean diet
Other: Mediterranean diet
Patients enrolled in this study will follow a Mediterranean diet for a 6 month period.
Metagenomic sequencing
Subjects will adhere to 6 months of exclusive Mediterranean Diet and have post diet intervention analysis of 16s and metagenomic sequencing, cytokine and metabolomic analysis for microbiome assessment.
Time frame: 6 months
Fecal calprotectin
Fecal calprotectin as a marker of intestinal inflammation. Patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) for symptom reporting.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jun 2027, 9 months later.
Of 214 non-industry interventional studies with no phase under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 9 months is below that.
Counting every sponsor, half of 229 studies reached it within 24 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dartmouth-Hitchcock Medical Center →